STIFEL 2026 HEALTHCARE CONFERENCE - ABCELLERA BIOLOGICS INC

Financial Performance:

• No specific financial figures (revenue, earnings, cash flow, or debt) were disclosed in the transcript, as the company is pre-revenue and focused on clinical development.
• The company emphasizes the potential for ABCL-635 to be a "blockbuster product," with management noting current market potential "multiples" of prior blockbuster projections.
• Management noted a potential for higher pricing than current small molecules (which net ~$5,000/year) due to superior efficacy and safety, though exact pricing strategies remain under commercial review.

Guidance and Future Outlook:

• Late-Stage Initiation: ABCL-635 is expected to enter Phase 3 (registrational) trials next year.
• Oncology Expansion: Proof-of-concept studies for ABCL-635 in breast and prostate cancer indications are scheduled to begin next year.
• Data Readouts: Full Phase 2 Open Label Extension (OLE) data, including a second efficacy readout for patients receiving a second dose, is expected to be shared early next year.
• Pipeline Cadence: Strategy to advance 1–2 new development candidates to the clinic annually, with ABCL-688 and ABCL-386 currently in IND-enabling studies aiming for clinical entry next year.

Business Segments and Product Lines:

• ABCL-635 (Lead Asset): A first-in-class NK3R antagonist antibody for non-hormonal treatment of vasomotor symptoms (hot flashes) in menopause and hormone-deprivation cancer therapy.
  • Efficacy: Phase 2 data showed a 50% placebo-controlled reduction in hot flash frequency (double that of small molecules like fezolinetant) and 3.5–5x greater reduction in severity.
  • Safety: Clean safety profile with no liver toxicity signals, a known liability for current small molecule competitors.
  • Dosing: Potential regimen of 600mg loading dose followed by 300mg monthly maintenance, designed for a 2mL auto-injector.
• ABCL-992 (Next-Gen): A half-life extended analog of ABCL-635 under development to potentially reduce dosing frequency (e.g., to every 3 months), improving Cost of Goods Sold (COGS) and supply logistics.
• Other Pipeline Candidates: ABCL-385 (undisclosed oncology) and ABCL-646 (first-in-class ion channel antagonist) are in development, with undisclosed programs to be announced as they advance.

Market and Competitive Landscape:

• Competitive Set: Competes with approved small molecules Aranesp (fezolinetant) and Viosca (elenzanitant). Management claims ABCL-635 offers superior efficacy and safety compared to these agents.
• Market Tailwinds: Increased demand for non-hormonal therapies driven by supply shortages of hormone therapy patches and the recent removal of FDA boxed warnings for hormone therapy, leading to a surge in patient demand.
• Market Expansion: Superior efficacy comparable to hormone therapy is expected to capture patients who previously opted out of hormone therapy due to safety concerns or side effects.
• Distribution Shift: Commercial strategy anticipates a shift from traditional OB/GYN channels to Primary Care and Direct-to-Consumer (DTC) telehealth models, leveraging high patient self-diagnosis capabilities and direct delivery.

Risks and Challenges:

• Clinical Trial Design: High screen failure rates (historically ~65-75%) driven by patient diaries and strict inclusion criteria for symptom frequency, requiring careful patient selection.
• Regulatory Uncertainty: While enrolled in the FDA's Model-Informed Drug Development (MIDD) program, final Phase 3 dosing and trial design still require regulatory alignment and cannot be fully assumed without confirmation.
• Competition: Competitors may launch similar half-life extended antibodies, requiring Abcelera to effectively differentiate on dosing convenience, price, and indication strategy.
• Commercial Execution: Uncertainty regarding the viability and profitability of the emerging DTC/telehealth model compared to traditional pharmaceutical sales forces.

Management Commentary and Tone:

• Tone: Highly confident and enthusiastic; management described the Phase 2 results as a "killer product" that exceeded even their "upside scenario."
• Strategic Clarity: Carl Hansen (CEO) emphasized the company is "all in" on ABCL-635 while simultaneously advancing next-gen options (ABCL-992) to defend the lead.
• Platform Narrative: Repeatedly stated the company is "not a one-trick pony," highlighting a platform capable of delivering multiple first-in-class candidates.
• Market Timing: Management expressed strong belief that current market conditions (supply constraints of HT, rising DTC adoption) are ideal for a non-hormonal alternative.

Analyst Questions and Answers:

• Q: What drives the breakthrough efficacy vs. small molecules? A: Receptor occupancy; antibodies allow higher dosing to fully shut down NK3R receptors without the liver toxicity ceiling limiting small molecules.
• Q: Will efficacy persist after the initial dose? A: Baseline expectation is persistence based on small molecule data, but OLE data will confirm; 37% of patients achieved complete resolution at week 4.
• Q: How does sleep improvement compare to dual antagonists like Linquit? A: ABCL-635 (NK3R only) achieved sleep scores equivalent to Linquit (NK1/NK3) without the somnolence risk, attributed to the superior reduction in hot flash frequency.
• Q: What is the Phase 3 timeline and size? A: Targeting ~1,500 patients (aligning with competitors but potentially smaller due to safety profile); timeline benchmarked at ~2.5 years from first patient in, though potential for acceleration exists.
• Q: How will commercialization be handled? A: Exploring both partnership with large pharma and independent DTC execution, capitalizing on the "GLP-1 style" DTC model for self-administered therapies.
• Q: Is ABCL-992 a defensive move? A: It is an offensive strategy to lower COGS and increase supply, potentially allowing for quarterly dosing, offering a commercial advantage in scale and cost.

Other Key Points:

• Study Design: Phase 2 was a single-dose study (600mg) with a 4-week efficacy readout, followed by an 8-week washout and a second dose in the OLE to model PK/PD for Phase 3.
• Regulatory Engagement: Abcelera has been admitted to the FDA's MIDD program to use sophisticated modeling to inform Phase 3 dosing without extensive empirical dose-ranging trials.
• Patient Retention: High patient compliance in the Phase 2 trial (mid-to-high 90%) in diary completion.
• Long-term Therapy: Hot flashes can persist for 7–20 years, suggesting a long-term treatment duration and recurring revenue potential.
• Geographic Focus: Phase 2 was conducted in Canada; Phase 3 is planned to be global (US, Canada, Australia, Europe).